Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro(TM) Testing Method

Stock Information for Elutia Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Elutia Inc.

Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development
Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21
Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation
Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
Elutia Selected to Exhibit EluPro(TM) Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.